{"success":true,"data":{"pressRelease":{"id":"68893","rtpr_id":"nACSKgVwja","ticker":"ONCO","exchange":"CBOE","all_tickers":["ONCO"],"title":"Onco-Innovations Announces Non-Brokered LIFE Offering","author":"ACCESSWIRE","published_at":"2026-06-19T23:00:00.402Z","article_body":"Not for distribution to United States wire services or for dissemination in\nthe United States\n\nVANCOUVER, BC / ACCESS Newswire (https://www.accessnewswire.com/) / June 19,\n2026 / Onco-Innovations Limited (CBOE:ONCO) (\"Onco\" or the \"Company\") is\npleased to announce that it intends to complete a non-brokered private\nplacement (the \"Private Placement\") of units of the Company (each, a \"Unit\"),\npursuant to which it will offer 6,764,069 Units at a price of CAD$0.7392 per\nUnit for aggregate gross proceeds of approximately CAD$5,000,000 pursuant to\nthe Listed Issuer Financing Exemption (as defined below). Each Unit is\ncomprised of one common share (each a \"Share\") and one common share purchase\nwarrant (a \"Warrant\"), with each Warrant entitling the holder to purchase one\nShare at a price of CAD$0.90 for a period of three years following the closing\ndate of the Private Placement, which is expected to occur on or about July 10,\n2026, subject to certain conditions, including the receipt of all necessary\nregulatory approvals, including the approval of Cboe Canada Inc. (the \"Cboe\").\n\nThe Private Placement will not close unless subscriptions for at least\n6,764,069 Units have been received. If the minimum subscription is not\nachieved, all subscription funds will be returned to subscribers in accordance\nwith applicable securities laws.\n\nThe net proceeds from the Private Placement will be used to advance the\ndevelopment of its ONC010 program through key stages of its clinical\ndevelopment pathway, including manufacturing and preclinical testing\nactivities, for the development of the SynoGraph™ platform and for general\nworking capital and corporate purposes.\n\nThe Warrants shall provide that if the 10-day volume-weighted average trading\nprice of the Shares on the Cboe (or such other exchange on which the Shares\nare then listed) is equal to or greater than CAD$1.30 at the close of any\ntrading day, the Company may, at its option, accelerate the expiry date of the\nWarrants by issuing a news release announcing that the expiry date of the\nWarrants will be deemed to be the 30(th) day following the date of such news\nrelease.\n\nSubject to compliance with applicable regulatory requirements and in\naccordance with National Instrument 45-106 Prospectus Exemptions (\"NI\n45-106\"), the Units will be offered for sale to purchasers resident in all\nprovinces of Canada except Quebec pursuant to the listed issuer financing\nexemption under Part 5A of NI 45-106 as amended by Coordinated Blanket Order\n45-935 Exemptions from Certain Conditions of the Listed Issuer Financing\nExemption (the \"Listed Issuer Financing Exemption\") as well as certain\noffshore purchasers. Because the Private Placement is being completed pursuant\nto the Listed Issuer Financing Exemption, the Units issued pursuant to the\nPrivate Placement will not be subject to a hold period pursuant to applicable\nCanadian securities laws. There is an offering document related to the Private\nPlacement that can be accessed under the Company's issuer profile on SEDAR+ at\nwww.sedarplus.ca and on the Company's website at www.oncoinnovations.com.\nProspective investors should read the offering document before making an\ninvestment decision.\n\nThe securities described herein have not been and will not be registered under\nthe United States Securities Act of 1933, as amended, or any U.S. state\nsecurities laws, and may not be offered or sold in the United States absent\nregistration or available exemptions from such registration requirements. This\npress release does not constitute an offer to sell or a solicitation of an\noffer to buy any securities in the United States, or in any jurisdiction in\nwhich such offer, solicitation or sale would be unlawful.\n\nAbout Onco-Innovations Limited\n\nOnco-Innovations is a Canadian-based company dedicated to cancer research and\ntreatment, specializing in oncology. Onco's mission is to pursue the\nprevention and treatment of cancer through pioneering research and innovative\nsolutions. The Company has secured an exclusive worldwide license to patented\ntechnology that targets solid tumours.\n\nON BEHALF OF ONCO-INNOVATIONS LIMITED,\n\n\"Thomas O'Shaughnessy\"\n\nChief Executive Officer\n\nFor more information, please contact:\n\nThomas O'Shaughnessy,\nChief Executive Officer\nTel: + 1 888 261 8055\ninvestors@oncoinnovations.com\n\nThe Cboe has not reviewed and does not accept responsibility for the accuracy\nor adequacy of this release.\n\nCautionary Note Regarding Forward-Looking Information\n\nThis news release contains \"forward-looking information\" within the meaning of\napplicable securities laws (\"forward-looking statements\"), including, without\nlimitation, statements regarding: the completion of the Private Placement and\nthe timing thereof; the Company's ability to satisfy the minimum subscription\ncondition; receipt of all required regulatory approvals, including approval of\nCboe Canada Inc.; the anticipated closing date of the Private Placement; the\nintended use of proceeds; the terms and potential exercise of the Warrants;\nand the Company's business objectives and planned research and development\nactivities.\n\nForward-looking statements are often identified by words such as \"intend\",\n\"expect\", \"anticipate\", \"believe\", \"may\", \"will\", \"plan\", \"potential\" and\nsimilar expressions. These statements are based on current expectations,\nestimates and assumptions made by management in light of its experience and\nperception of historical trends.\n\nForward-looking statements are subject to a variety of known and unknown\nrisks, uncertainties and other factors that may cause actual results,\nperformance or achievements of the Company to be materially different from\nthose expressed or implied by such forward-looking statements. Such factors\ninclude, without limitation: the Company's ability to complete the Private\nPlacement on the terms described herein or at all; the risk that the minimum\nsubscription condition is not satisfied; the availability of investors; the\nreceipt of all necessary regulatory approvals; general capital market\nconditions; the Company's ability to execute its business and research and\ndevelopment plans; the availability of additional financing on acceptable\nterms; and other risks and uncertainties disclosed in the Company's continuous\ndisclosure filings available under its profile on SEDAR+.\n\nForward-looking statements are based on certain assumptions that management\nbelieves are reasonable at the time such statements are made, including,\nwithout limitation: that the Company will be able to complete the Private\nPlacement within the anticipated timeframe; that the necessary investor demand\nwill be obtained to satisfy the minimum subscription condition; that all\nrequired regulatory approvals will be obtained in a timely manner; and that\nthe Company will be able to deploy the proceeds of the Private Placement in\naccordance with its business objectives.\n\nAlthough the Company believes that the expectations reflected in the\nforward-looking statements are reasonable, there can be no assurance that such\nexpectations will prove to be correct. Readers are cautioned not to place\nundue reliance on forward-looking statements, as actual results may differ\nmaterially from those expressed or implied herein.\n\nThe forward-looking statements contained in this news release are made as of\nthe date hereof, and the Company undertakes no obligation to update or revise\nsuch statements except as required by applicable securities laws.\n\nSOURCE: Onco-Innovations Limited\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/onco-innovations-announces-non-brokered-life-offering-1179689)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSKgVwja","title":"Onco-Innovations Announces Non-Brokered LIFE Offering","author":"ACCESSWIRE","ticker":"ONCO","created":"2026-06-19T23:00:00.402Z","tickers":["ONCO"],"exchange":"CBOE","article_body":"Not for distribution to United States wire services or for dissemination in\nthe United States\n\nVANCOUVER, BC / ACCESS Newswire (https://www.accessnewswire.com/) / June 19,\n2026 / Onco-Innovations Limited (CBOE:ONCO) (\"Onco\" or the \"Company\") is\npleased to announce that it intends to complete a non-brokered private\nplacement (the \"Private Placement\") of units of the Company (each, a \"Unit\"),\npursuant to which it will offer 6,764,069 Units at a price of CAD$0.7392 per\nUnit for aggregate gross proceeds of approximately CAD$5,000,000 pursuant to\nthe Listed Issuer Financing Exemption (as defined below). Each Unit is\ncomprised of one common share (each a \"Share\") and one common share purchase\nwarrant (a \"Warrant\"), with each Warrant entitling the holder to purchase one\nShare at a price of CAD$0.90 for a period of three years following the closing\ndate of the Private Placement, which is expected to occur on or about July 10,\n2026, subject to certain conditions, including the receipt of all necessary\nregulatory approvals, including the approval of Cboe Canada Inc. (the \"Cboe\").\n\nThe Private Placement will not close unless subscriptions for at least\n6,764,069 Units have been received. If the minimum subscription is not\nachieved, all subscription funds will be returned to subscribers in accordance\nwith applicable securities laws.\n\nThe net proceeds from the Private Placement will be used to advance the\ndevelopment of its ONC010 program through key stages of its clinical\ndevelopment pathway, including manufacturing and preclinical testing\nactivities, for the development of the SynoGraph™ platform and for general\nworking capital and corporate purposes.\n\nThe Warrants shall provide that if the 10-day volume-weighted average trading\nprice of the Shares on the Cboe (or such other exchange on which the Shares\nare then listed) is equal to or greater than CAD$1.30 at the close of any\ntrading day, the Company may, at its option, accelerate the expiry date of the\nWarrants by issuing a news release announcing that the expiry date of the\nWarrants will be deemed to be the 30(th) day following the date of such news\nrelease.\n\nSubject to compliance with applicable regulatory requirements and in\naccordance with National Instrument 45-106 Prospectus Exemptions (\"NI\n45-106\"), the Units will be offered for sale to purchasers resident in all\nprovinces of Canada except Quebec pursuant to the listed issuer financing\nexemption under Part 5A of NI 45-106 as amended by Coordinated Blanket Order\n45-935 Exemptions from Certain Conditions of the Listed Issuer Financing\nExemption (the \"Listed Issuer Financing Exemption\") as well as certain\noffshore purchasers. Because the Private Placement is being completed pursuant\nto the Listed Issuer Financing Exemption, the Units issued pursuant to the\nPrivate Placement will not be subject to a hold period pursuant to applicable\nCanadian securities laws. There is an offering document related to the Private\nPlacement that can be accessed under the Company's issuer profile on SEDAR+ at\nwww.sedarplus.ca and on the Company's website at www.oncoinnovations.com.\nProspective investors should read the offering document before making an\ninvestment decision.\n\nThe securities described herein have not been and will not be registered under\nthe United States Securities Act of 1933, as amended, or any U.S. state\nsecurities laws, and may not be offered or sold in the United States absent\nregistration or available exemptions from such registration requirements. This\npress release does not constitute an offer to sell or a solicitation of an\noffer to buy any securities in the United States, or in any jurisdiction in\nwhich such offer, solicitation or sale would be unlawful.\n\nAbout Onco-Innovations Limited\n\nOnco-Innovations is a Canadian-based company dedicated to cancer research and\ntreatment, specializing in oncology. Onco's mission is to pursue the\nprevention and treatment of cancer through pioneering research and innovative\nsolutions. The Company has secured an exclusive worldwide license to patented\ntechnology that targets solid tumours.\n\nON BEHALF OF ONCO-INNOVATIONS LIMITED,\n\n\"Thomas O'Shaughnessy\"\n\nChief Executive Officer\n\nFor more information, please contact:\n\nThomas O'Shaughnessy,\nChief Executive Officer\nTel: + 1 888 261 8055\ninvestors@oncoinnovations.com\n\nThe Cboe has not reviewed and does not accept responsibility for the accuracy\nor adequacy of this release.\n\nCautionary Note Regarding Forward-Looking Information\n\nThis news release contains \"forward-looking information\" within the meaning of\napplicable securities laws (\"forward-looking statements\"), including, without\nlimitation, statements regarding: the completion of the Private Placement and\nthe timing thereof; the Company's ability to satisfy the minimum subscription\ncondition; receipt of all required regulatory approvals, including approval of\nCboe Canada Inc.; the anticipated closing date of the Private Placement; the\nintended use of proceeds; the terms and potential exercise of the Warrants;\nand the Company's business objectives and planned research and development\nactivities.\n\nForward-looking statements are often identified by words such as \"intend\",\n\"expect\", \"anticipate\", \"believe\", \"may\", \"will\", \"plan\", \"potential\" and\nsimilar expressions. These statements are based on current expectations,\nestimates and assumptions made by management in light of its experience and\nperception of historical trends.\n\nForward-looking statements are subject to a variety of known and unknown\nrisks, uncertainties and other factors that may cause actual results,\nperformance or achievements of the Company to be materially different from\nthose expressed or implied by such forward-looking statements. Such factors\ninclude, without limitation: the Company's ability to complete the Private\nPlacement on the terms described herein or at all; the risk that the minimum\nsubscription condition is not satisfied; the availability of investors; the\nreceipt of all necessary regulatory approvals; general capital market\nconditions; the Company's ability to execute its business and research and\ndevelopment plans; the availability of additional financing on acceptable\nterms; and other risks and uncertainties disclosed in the Company's continuous\ndisclosure filings available under its profile on SEDAR+.\n\nForward-looking statements are based on certain assumptions that management\nbelieves are reasonable at the time such statements are made, including,\nwithout limitation: that the Company will be able to complete the Private\nPlacement within the anticipated timeframe; that the necessary investor demand\nwill be obtained to satisfy the minimum subscription condition; that all\nrequired regulatory approvals will be obtained in a timely manner; and that\nthe Company will be able to deploy the proceeds of the Private Placement in\naccordance with its business objectives.\n\nAlthough the Company believes that the expectations reflected in the\nforward-looking statements are reasonable, there can be no assurance that such\nexpectations will prove to be correct. Readers are cautioned not to place\nundue reliance on forward-looking statements, as actual results may differ\nmaterially from those expressed or implied herein.\n\nThe forward-looking statements contained in this news release are made as of\nthe date hereof, and the Company undertakes no obligation to update or revise\nsuch statements except as required by applicable securities laws.\n\nSOURCE: Onco-Innovations Limited\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/onco-innovations-announces-non-brokered-life-offering-1179689)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-06-19T23:00:00.448924164Z","server_sent_at_ms":1781910000448},"received_at":"2026-06-19T23:00:00.501Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/onco-innovations-announces-non-brokered-life-offering-1179689"},"analysis":{"id":"58305","press_release_id":"68893","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Significant dilution: ~6.8M new shares issued for a small-cap biotech","Warrants exercisable at CAD$0.90 create overhang above offering price of CAD$0.7392","Minimum subscription condition: deal may fail if not fully subscribed"],"eventType":"offering","narrative":"Onco-Innovations announced a non-brokered private placement of 6,764,069 units at CAD$0.7392 per unit, raising approximately CAD$5 million.\n\nEach unit consists of one common share and one warrant exercisable at CAD$0.90 for three years. The company intends to use proceeds for the ONC010 clinical program and the SynoGraph platform.\n\nThe deal is subject to a minimum subscription condition and Cboe approval, with closing expected around July 10, 2026. The offering is exempt from US registration and restricted to Canadian and offshore investors.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"ONCO raises CAD$5M via dilutive private placement to fund ONC010 clinical trials; warrants add overhang."},"keyFigures":{"dealValueUsd":"CAD$5,000,000","offeringPrice":"CAD$0.7392","sharesOffered":6764069,"customDimensions":{"warrant_exercise_price":"CAD$0.90","warrant_acceleration_trigger":"CAD$1.30"}},"quotedText":"Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology.","namedEntities":{"people":[{"name":"Thomas O'Shaughnessy","role":"Chief Executive Officer"}],"products":["ONC010","SynoGraph"],"companies":[{"name":"Onco-Innovations Limited","ticker":"ONCO","relationship":"filer"},{"name":"Cboe Canada Inc.","relationship":"regulatory/exchange"}],"dollarAmounts":[{"amount":"CAD$0.7392","context":"price per Unit"},{"amount":"CAD$5,000,000","context":"aggregate gross proceeds"},{"amount":"CAD$0.90","context":"warrant exercise price"},{"amount":"CAD$1.30","context":"warrant acceleration trigger price"}]},"materialImpact":{"score":3,"reasoning":"The company is raising CAD$5 million via a private placement of ~6.8 million units. For a small-cap biotech, this represents significant dilution (likely >10-20% of float) and signals a need for cash to fund clinical development. The non-brokered nature and LIFE exemption suggest a targeted, potentially less efficient raise."},"tickerRelevance":{"others":[],"primary":"ONCO"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"dilutive financing","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"high dilution impact for small float","retailFavoriteBoost":0}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":3,"narrative":"Onco-Innovations announced a non-brokered private placement of 6,764,069 units at CAD$0.7392 per unit, raising approximately CAD$5 million.\n\nEach unit consists of one common share and one warrant exercisable at CAD$0.90 for three years. The company intends to use proceeds for the ONC010 clinical program and the SynoGraph platform.\n\nThe deal is subject to a minimum subscription condition and Cboe approval, with closing expected around July 10, 2026. The offering is exempt from US registration and restricted to Canadian and offshore investors.","key_figures":{"dealValueUsd":"CAD$5,000,000","offeringPrice":"CAD$0.7392","sharesOffered":6764069,"customDimensions":{"warrant_exercise_price":"CAD$0.90","warrant_acceleration_trigger":"CAD$1.30"}},"named_entities":{"people":[{"name":"Thomas O'Shaughnessy","role":"Chief Executive Officer"}],"products":["ONC010","SynoGraph"],"companies":[{"name":"Onco-Innovations Limited","ticker":"ONCO","relationship":"filer"},{"name":"Cboe Canada Inc.","relationship":"regulatory/exchange"}],"dollarAmounts":[{"amount":"CAD$0.7392","context":"price per Unit"},{"amount":"CAD$5,000,000","context":"aggregate gross proceeds"},{"amount":"CAD$0.90","context":"warrant exercise price"},{"amount":"CAD$1.30","context":"warrant acceleration trigger price"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-19T23:00:17.395Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"dilutive financing","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"high dilution impact for small float","retailFavoriteBoost":0}},"durationMs":16883,"modelName":"george-droid-qwen-72b"}}